+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Opioid-Induced Constipation Market 2018-2022 - Product Image

Global Opioid-Induced Constipation Market 2018-2022

  • ID: 4721375
  • Report
  • December 2018
  • Region: Global
  • 98 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AstraZeneca
  • Bausch Health
  • Merck
  • Takeda Pharmaceutical
  • MORE
Rise in incidence of chronic diseases such as arthritis, back pain, and migraine is likely to drive growth in the market. The incidence of chronic pain is increasing across the world, owing to the several reasons, including lifestyle changes, rise in number of injuries, growth in number of surgeries, and painful medical conditions. The analysts have predicted that the opioid-induced constipation market will register a CAGR of more than 32% by 2022.

Market Overview

Rise in OIC cases among elderly

Rise in incidences of diseases associated with old age, impaired body functions, and increase in the use of medicines such as antidepressants and anticholinergics have collectively led to high prevalence of constipation among the elderly population. This drives growth in the opioid-induced constipation market.

Use of conventional laxatives for OIC

The use of laxatives for OIC is a major challenge that is reducing sales of approved drugs meant for the treatment of OIC.

For the detailed list of factors that will drive and challenge the growth of the opioid-induced constipation market during the 2018-2022, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Takeda Pharmaceutical and Merck, the competitive environment is quite intense. Factors such as the rise in incidence of chronic diseases such as arthritis, back pain, and migraine and the rise in OIC cases among elderly, will provide considerable growth opportunities to opioid-induced constipation manufactures. AstraZeneca, Bausch Health, Takeda Pharmaceutical, and Merck are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Bausch Health
  • Merck
  • Takeda Pharmaceutical
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: PIPELINE ANALYSIS
  • Pipeline analysis
PART 06: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION
  • Segmentation by route of administration
  • Comparison by application
  • Oral - Market size and forecast 2017-2022
  • Parenteral - Market size and forecast 2017-2022
  • Market opportunity by application
PART 09: MARKET SEGMENTATION BY CLASS OF DRUGS
  • Segmentation by class of drugs
  • Peripherally acting mu-opioid receptor antagonist
  • Locally acting chloride channel activator
  • Others
PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • Market opportunity
PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 14: MARKET TRENDS
  • Rise in incidence of chronic diseases such as arthritis, back pain, and migraine
  • Market dominance by opioid receptor antagonists
  • Introduction of separate diagnostic guidelines for idiopathic or functional constipation and OIC
PART 15: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 16: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Bausch Health
  • Takeda Pharmaceutical
  • Merck
PART 17: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for OIC
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global - Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: Route of administration - Market share 2017-2022 (%)
Exhibit 20: Comparison by application
Exhibit 21: Oral - Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Oral route - Year-over-year growth 2018-2022 (%)
Exhibit 23: Parenteral - Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Parenteral route - Year-over-year growth 2018-2022 (%)
Exhibit 25: Market opportunity by application
Exhibit 26: Customer landscape
Exhibit 27: Global - Market share by geography 2017-2022 (%)
Exhibit 28: Regional comparison
Exhibit 29: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 30: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 33: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 34: Top 3 countries in APAC
Exhibit 35: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 36: EMEA - year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in EMEA
Exhibit 38: Market opportunity
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: AstraZeneca overview
Exhibit 44: AstraZeneca - Business segments
Exhibit 45: AstraZeneca - Organizational developments
Exhibit 46: AstraZeneca - Geographic focus
Exhibit 47: AstraZeneca - Key offerings
Exhibit 48: Bausch Health overview
Exhibit 49: Bausch Health - Business segments
Exhibit 50: Bausch Health - Organizational developments
Exhibit 51: Bausch Health - Geographic focus
Exhibit 52: Bausch Health - Segment focus
Exhibit 53: Bausch Health - Key offerings
Exhibit 54: Takeda Pharmaceutical overview
Exhibit 55: Takeda Pharmaceutical - Business segments
Exhibit 56: Takeda Pharmaceutical - Organizational developments
Exhibit 57: Takeda Pharmaceutical - Geographic focus
Exhibit 58: Takeda Pharmaceutical - Key offerings
Exhibit 59: Merck overview
Exhibit 60: Merck - Business segments
Exhibit 61: Merck - Organizational developments
Exhibit 62: Merck - Geographic focus
Exhibit 63: Merck - Segment focus
Exhibit 64: Merck - Key offerings
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Bausch Health
  • Merck
  • Takeda Pharmaceutical
  • MORE
Global Opioid-Induced Constipation Market 2018-2022

The analyst recognizes the following companies as the key players in the global opioid-induced constipation market: AstraZeneca, Bausch Health, Takeda Pharmaceutical, and Merck.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the rise in incidence of chronic diseases such as arthritis, back pain, and migraine.”

According to the report, one of the major drivers for this market is the rise in OIC cases among elderly.

Further, the report states that one of the major factors hindering the growth of this market is the use of conventional laxatives for OIC.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca
  • Bausch Health
  • Takeda Pharmaceutical
  • Merck
Note: Product cover images may vary from those shown
Adroll
adroll